Jafron Biomedical

Jafron Biomedical Co., Ltd. (stock code: 300529) was founded in 1989, headquartered in Zhuhai, a core city of the Guangdong-Hong Kong-Macao Greater Bay Area. The company specializes in the research, development, production, and sales of biomaterials and high-tech medical devices. It is a key high-tech enterprise under the National Torch Plan, honored with the "National Science and Technology Progress Second Prize," "National Manufacturing Single Champion Demonstration Enterprise," "National Technological Innovation Demonstration Enterprise," and "National Harmonious Labor Relations Demonstration Enterprise." It undertakes multiple national science and technology and industrialization projects, and possesses research platforms such as the National Enterprise Technology Center, Academician Workstation, and Postdoctoral Workstation. As an A-share ChiNext listed company with blood purification products as its main business, its market value consistently ranks among the forefront of medical device listed companies.

The company's original and innovative series of hemoperfusion cartridges and blood adsorption columns command a market share of over 70%. Widely applied in fields such as poisoning, critical care, kidney disease, liver disease, and autoimmune diseases, they treat hundreds of thousands of patients annually, are sold to more than 8,000 large and medium-sized hospitals across China, and are exported to over 90 countries and regions.

Jafron is committed to building a unique, integrated blood purification industry chain encompassing equipment, consumables, pharmaceuticals, insurance, chronic disease management, and medical services, achieving group-based, brand-oriented, and diversified development, laying a solid foundation for the vision of becoming a "world-class high-tech medical technology enterprise group."